A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

NCT01584648 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

423

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib
DRUG: Trametinib placebo

Sponsor

Novartis Pharmaceuticals